2 tracked public figures made calls on VYGR. We grade SELL/REDUCE calls as Correct/Incorrect/Pending, and compare BUY/ADD returns against the S&P 500 over matched windows.
On average, public BUY calls on Voyager Therapeutics trailed the S&P 500 by +18.3%.
| Who | Signal | Date | Return / Grade | Buy vs S&P | Source |
|---|---|---|---|---|---|
| Charlie Scharf | BUY | Mar 12, 2026 | -20.9% | -2.6% | source ↗ |
| Scott Minerd | BUY | Mar 12, 2026 | -20.9% | -2.6% | source ↗ |
Charlie Scharf currently ranks #1 on VYGR with -20.9% average buy return vs -2.6% for the S&P 500 (-18.3% alpha) across 1 scored buy calls.
No. Across 2 scored BUY/ADD calls, average return is -20.9% vs -2.6% for the S&P 500 (-18.3% alpha).
SELL/REDUCE calls are shown as Correct, Incorrect, or Pending. Only BUY/ADD calls are compared directly against the S&P 500 in the ticker-level return stats.